KCT0006235Not yet recruiting未知

Oncologic outcome of multimodal treatment strategy with neoadjuvant oxaliplatin-based chemotherapy for obstructive colon cancer after colonoscopic stent decompression: a randomized controlled trial

The Catholic University of Korea, St. Vincent's Hospital0 sites204 target enrollmentStarted: TBDLast updated: June 24, 2021

Trial Snapshot

No summary available.

•i. Age : 20 years old or more and lesser than 75 years old
•ii. Agreement of this study
•iii. Clinical stage II or III colon cancer with colonic obstruction which is confirmed by pathologic review and imaging study.
•iv. Colon cancer located beween distal T colon and Rectosigmoid junction colon which is defined as a tumor above 15cm from anal verge.
•v. Colonocopic fiding: tumor involving whole circumference of the lumen, impossible to pass endoscope through the tumor
•vi. SEMS placement
•vii. no colonic injury and successful decompression of the colon with in 48 hours after SEMS placement.
•viii. ECOG performance 0-2
•ix. ASA = 3
•x. Appropriate function of the vital organ (acceptable liver enzyme and BUN/Cr)
•xi. Appropriate function of hematopoietic system (platelet =100,000ul, neutrophil =2,000ul)
•xii. If the patient is female in fertile period, urine hCG test is negative and she has no plan of pregnancy with 6 months after the termiation of whole treatment.
•xiii. If the patient is male in fertile period, he agrees with contraception during treatment period and 6 months after the termination of whole treatment.

•i. any suspicious distant metastasis
•ii. any other primary malignant lesion
•iii. Clinical stage T1or T2 and N0
•iv. the sign of perforation or severe ischemia requiring ememgency operation
•v. the complication related to SEMS placement (severe bleeding and perforation after SEMS placement)
•vi. ASA 4 or more
•vii. ECOG 3 or more
•viii. colonic obstruction by benign stricture
•ix. pregnant woman or woman who is breastfeeding
•x. the paitents who already enrolled into other study or are taking medicine related to any clinical trial
•xi. the patients who are taking sorivudine
•xii. the patients who are taking Tegafur/gimeracil/oteracil
•xiii. the patietns who have a medical history of hypersensitivity reaction to 5-FU, oxaliplatin, leucovorin,or any medication including platinum.
•xiv. Inappropriate function of vital organ (impaired renal function, elevated liver enzyme, and so on )
•xv. Inappropriate function of hematopoietic system (platelet <100,000ul, neutrophil < 2,000ul)
•xvi. Genetic problem such as galactose intolerance, Lapp lactase deficiency, or glucose-galatose malabsorption)

Sponsor